Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Universite De Nice Sophiea Antipolis, Assistance Publique-Hopitaux de Paris, Centre National De La Recherche Scientifique, Universite Paris Descartes
InventorsJohanna CHICHE, Jean Ehrland RICCI, Catherine THIEBLEMONT
Estimating the term…
The present invention relates to a method for predicting the responsiveness of a patient to a treatment with mtor inhibitors. Using primary Eμ-Myc lymphoma cells, inventors observed that Eμ-Myc-GAPDHhigh clones presented less mTOR activity than Eμ-Myc-GAPDHlow clones, as determined by the increase in p70-S6K phosphorylation in the latter. Importantly, inhibition of mTOR with rapamycin in two independent Eμ-Myc-GAPDHlow clones induces a metabolic shift from OxPhos to glycolysis. These results suggest that GAPDH-dependent modulation of the mTOR pathway controls the metabolic status of malignant B lymphocytes. Accordingly, the invention relates to a method for determining whether a subject suffering from lymphoma will achieve a response to a treatment with mTOR inhibitor and to a method of treating with an mTOR inhibitor the subject identified as responder.
A method for treating a subject suffering from lymphoma in need thereof with an mTOR inhibitor, wherein said method comprises the following steps:
Dependencies are inferred from the claim text.